PMID: 8938218Jan 1, 1996Paper

Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia

Acta Oncologica
P GlynneJ Mehta

Abstract

The serum creatinine level was used to determine the incidence of renal dysfunction in 70 adults with acute leukemia who were alive and well one year following autologous bone marrow transplantation (ABMT). Creatinine measurements at the time of ABMT, one year post-ABMT and at the last follow-up (12-128 months, median 35) were recorded, and a level of >120 micromol/l arbitrarily defined as clinically significant renal impairment. The incidence of renal impairment was 2.9% (n = 2) at 1 year, and 4.3% (n = 3) at the last follow-up in continuous remission. Significant renal impairment occurred after relapse in 8 of 12 patients, but was seen in only 3 of 58 patients who remained in remission (p < 0.001, Fisher's exact test), suggesting subclinical renal damage which became obvious with further nephrotoxic therapy. We conclude that clinically significant renal dysfunction is an uncommon long-term complication of ABMT, and should not be a concern in recommending this therapy to eligible patients.

References

Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S I BearmanE D Thomas
Jul 1, 1988·International Journal of Radiation Oncology, Biology, Physics·N J TarbellH J Weinstein

❮ Previous
Next ❯

Citations

Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J R WingardJ Lister
Oct 18, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M J EllisU D Patel
May 10, 2006·International Journal of Radiation Oncology, Biology, Physics·Henk B Kal, M Loes van Kempen-Harteveld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Sabina KerstingLeo F Verdonck
Bone Marrow Transplantation
Joana E Kist-van HoltheA J van der Heijden
© 2021 Meta ULC. All rights reserved